Citations (27)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Kristine A. Frerichs, Noemi Anna Nagy, Pieter L. Lindenbergh, Patty Bosman, Jhon Marin Soto, Marloes Broekmans, Richard W. J. Groen, Maria Themeli, Louise Nieuwenhuis, Claudia Stege, Inger S. Nijhof, Tuna Mutis, Sonja Zweegman, Henk M. Lokhorst & Niels W. C. J. van de Donk. (2018) CD38-targeting antibodies in multiple myeloma: mechanisms of action and clinical experience. Expert Review of Clinical Immunology 14:3, pages 197-206.
Read now
Read now
Stefania Oliva, Manuela Gambella, Mario Boccadoro & Sara Bringhen. (2017) Systemic virotherapy for multiple myeloma. Expert Opinion on Biological Therapy 17:11, pages 1375-1387.
Read now
Read now
Tadeusz Robak & Ewa Robak. (2014) Current Phase II antibody-drug conjugates for the treatment of lymphoid malignancies. Expert Opinion on Investigational Drugs 23:7, pages 911-924.
Read now
Read now
Articles from other publishers (24)
Julia Hambach, William Fumey, Tobias Stähler, Anna Josephine Gebhardt, Gerhard Adam, Katja Weisel, Friedrich Koch-Nolte & Peter Bannas. (2022) Half-Life Extended Nanobody-Based CD38-Specific Bispecific Killercell Engagers Induce Killing of Multiple Myeloma Cells. Frontiers in Immunology 13.
Crossref
Crossref
Daniele Derudas, Francesca Capraro, Giovanni Martinelli & Claudio Cerchione. (2020) How I Manage Frontline Transplant-Ineligible Multiple Myeloma. Hematology Reports 12:11, pages 8956.
Crossref
Crossref
Li Liu, William J Wertz, Anthony Kondisko, Michael R Shurin & Sarah E Wheeler. (2020) Incidence and Management of Therapeutic Monoclonal Antibody Interference in Monoclonal Gammopathy Monitoring. The Journal of Applied Laboratory Medicine 5:1, pages 29-40.
Crossref
Crossref
Barry PaulBrea Lipe, Enrique M. Ocio & Saad Z. Usmani. (2019) Induction Therapy for Newly Diagnosed Multiple Myeloma. American Society of Clinical Oncology Educational Book:39, pages e176-e186.
Crossref
Crossref
Maria Gavriatopoulou, Despoina Fotiou, Ioannis Ntanasis-Stathopoulos, Efstathios Kastritis, Evangelos Terpos & Meletios Athanasios Dimopoulos. (2018) How I treat elderly patients with plasma cell dyscrasias. Aging 10:12, pages 4248-4268.
Crossref
Crossref
Francesca Gay & Alessandra Larocca. (2018) Special problems in the management of elderly patients with multiple myeloma. European Journal of Internal Medicine 58, pages 64-69.
Crossref
Crossref
Alexander Zheleznyak, Monica Shokeen & Samuel Achilefu. (2018) Nanotherapeutics for multiple myeloma. WIREs Nanomedicine and Nanobiotechnology 10:6.
Crossref
Crossref
Merav Leiba, Suha Jarjoura, Waseem Abboud, Arnon Nagler, Ran Yahalom, Adrian Duek & Noam Yarom. (2018) Role of oral examination in newly diagnosed multiple myeloma patients: A safe and simple way to detect light chain amyloidosis. Oral Diseases 24:7, pages 1343-1348.
Crossref
Crossref
Alessandra Larocca, Sandra Maria Dold, Sonja Zweegman, Evangelos Terpos, Ralph Wäsch, Mattia D’Agostino, Sophia Scheubeck, Hartmut Goldschmidt, Francesca Gay, Michele Cavo, Heinz Ludwig, Christian Straka, Sara Bringhen, Holger W. Auner, Jo Caers, Martin Gramatzki, Massimo Offidani, Meletios A. Dimopoulos, Hermann Einsele, Mario Boccadoro, Pieter Sonneveld & Monika Engelhardt. (2018) Patient-centered practice in elderly myeloma patients: an overview and consensus from the European Myeloma Network (EMN). Leukemia 32:8, pages 1697-1712.
Crossref
Crossref
Alessandra Larocca, Roberto Mina, Francesca Gay, Sara Bringhen & Mario Boccadoro. (2017) Emerging drugs and combinations to treat multiple myeloma. Oncotarget 8:36, pages 60656-60672.
Crossref
Crossref
Pamela L. Clemens, Xiaoyu Yan, Henk M. Lokhorst, Sagar Lonial, Nedjad Losic, Imran Khan, Richard Jansson, Tahamtan Ahmadi, Kristen Lantz, Honghui Zhou, Thomas Puchalski & Xu Steven Xu. (2016) Pharmacokinetics of Daratumumab Following Intravenous Infusion in Relapsed or Refractory Multiple Myeloma After Prior Proteasome Inhibitor and Immunomodulatory Drug Treatment. Clinical Pharmacokinetics 56:8, pages 915-924.
Crossref
Crossref
Kejie Zhang, Aakash Desai, Dongfeng Zeng, Tiejun Gong, Peihua Lu & Michael Wang. (2016) Magic year for multiple myeloma therapeutics: Key takeaways from the ASH 2015 annual meeting. Oncotarget 8:6, pages 10748-10759.
Crossref
Crossref
Caitlin Costello. (2016) An update on the role of daratumumab in the treatment of multiple myeloma. Therapeutic Advances in Hematology 8:1, pages 28-37.
Crossref
Crossref
Inger S. NijhofLaurens E. FranssenMark-David LevinGerard M. J. BosAnnemiek BroijlSaskia K. KleinHarry R. KoeneAndries C. BloemAart BeekerLaura M. FaberEllen van der SpekPaula F. Ypma, Reinier RaymakersDick-Johan van Spronsen, Peter E. WesterweelRimke OostvogelsJeroen van VelzenBerris van KesselTuna MutisPieter SonneveldSonja ZweegmanHenk M. LokhorstNiels W. C. J. van de Donk. (2016) Phase 1/2 study of lenalidomide combined with low-dose cyclophosphamide and prednisone in lenalidomide-refractory multiple myeloma. Blood 128:19, pages 2297-2306.
Crossref
Crossref
Saad Usmani, Tahamtan Ahmadi, Yvette Ng, Annette Lam, Avinash Desai, Ravi Potluri & Maneesha Mehra. (2016) Analysis of Real-World Data on Overall Survival in Multiple Myeloma Patients With ≥3 Prior Lines of Therapy Including a Proteasome Inhibitor (PI) and an Immunomodulatory Drug (IMiD), or Double Refractory to a PI and an IMiD. The Oncologist 21:11, pages 1355-1361.
Crossref
Crossref
Inger S. NijhofTineke CasneufJeroen van VelzenBerris van KesselAmy E. Axel, Khaja Syed, Richard W. J. GroenMark van Duin, Pieter Sonneveld, Monique C. MinnemaSonja ZweegmanChristopher Chiu, Andries C. BloemTuna MutisHenk M. LokhorstA. Kate Sasser & Niels W. C. J. van de Donk. (2016) CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma. Blood 128:7, pages 959-970.
Crossref
Crossref
Tomas Jelinek & Roman Hajek. (2016) Monoclonal antibodies — A new era in the treatment of multiple myeloma. Blood Reviews 30:2, pages 101-110.
Crossref
Crossref
Niels W. C. J. van de DonkPhilippe MoreauTorben PlesnerAntonio PalumboFrancesca GayJacob P. LaubachFabio MalavasiHervé Avet-LoiseauMaria-Victoria Mateos, Pieter Sonneveld, Henk M. LokhorstPaul G. Richardson. (2016) Clinical efficacy and management of monoclonal antibodies targeting CD38 and SLAMF7 in multiple myeloma. Blood 127:6, pages 681-695.
Crossref
Crossref
Vittorio Emanuele Muccio, Elona Saraci, Milena Gilestro, Valter Gattei, Antonella Zucchetto, Monica Astolfi, Marina Ruggeri, Eleonora Marzanati, Roberto Passera, Antonio Palumbo, Mario Boccadoro & Paola Omedè. (2016) Multiple myeloma: New surface antigens for the characterization of plasma cells in the era of novel agents. Cytometry Part B: Clinical Cytometry 90:1, pages 81-90.
Crossref
Crossref
Tadeusz Robak & Pawel Robak. 2015. Resistance to Immunotoxins in Cancer Therapy. Resistance to Immunotoxins in Cancer Therapy
89
128
.
Niels W.C.J. van de Donk & Pieter Sonneveld. (2014) Diagnosis and Risk Stratification in Multiple Myeloma. Hematology/Oncology Clinics of North America 28:5, pages 791-813.
Crossref
Crossref
Jianhong Chu, Shun He, Youcai Deng, Jianying Zhang, Yong Peng, Tiffany Hughes, Ling Yi, Chang-Hyuk Kwon, Qi-En Wang, Steven M. Devine, Xiaoming He, Xue-Feng Bai, Craig C. Hofmeister & Jianhua Yu. (2014) Genetic Modification of T Cells Redirected toward CS1 Enhances Eradication of Myeloma Cells. Clinical Cancer Research 20:15, pages 3989-4000.
Crossref
Crossref
J Chu, Y Deng, D M Benson, S He, T Hughes, J Zhang, Y Peng, H Mao, L Yi, K Ghoshal, X He, S M Devine, X Zhang, M A Caligiuri, C C Hofmeister & J Yu. (2013) CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma. Leukemia 28:4, pages 917-927.
Crossref
Crossref
Hermann Einsele. 2014. Small Molecules in Oncology. Small Molecules in Oncology
325
345
.